S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
The $193 Billion US-China War You Don't Know About (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
ChatGPT Is Already "Old School" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
ChatGPT Is Already "Old School" (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
The $193 Billion US-China War You Don't Know About (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
ChatGPT Is Already "Old School" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
ChatGPT Is Already "Old School" (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
The $193 Billion US-China War You Don't Know About (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
ChatGPT Is Already "Old School" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
ChatGPT Is Already "Old School" (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
The $193 Billion US-China War You Don't Know About (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
ChatGPT Is Already "Old School" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
ChatGPT Is Already "Old School" (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
NASDAQ:RKDA

Arcadia Biosciences (RKDA) Stock Forecast, Price & News

$4.59
+0.13 (+2.91%)
(As of 05/31/2023 ET)
Compare
Today's Range
$4.52
$4.71
50-Day Range
$4.21
$7.87
52-Week Range
$4.18
$60.00
Volume
13,350 shs
Average Volume
48,670 shs
Market Capitalization
$3.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Arcadia Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
313.9% Upside
$19.00 Price Target
Short Interest
Healthy
2.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Arcadia Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$21,550 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($18.44) to ($6.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars


RKDA stock logo

About Arcadia Biosciences (NASDAQ:RKDA) Stock

Arcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include GoodWheat pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.

Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
8-K: Arcadia Biosciences, Inc.
Q1 2023 Arcadia Biosciences Inc Earnings Call
Arcadia Biosciences reports Q1 results
Arcadia Biosciences (RKDA) to Release Earnings on Thursday
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Earnings Preview For Arcadia Biosciences
See More Headlines
Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Company Calendar

Last Earnings
3/30/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:RKDA
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+313.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,380,000.00
Net Margins
-245.87%
Pretax Margin
-247.08%

Debt

Sales & Book Value

Annual Sales
$9.96 million
Book Value
$19.46 per share

Miscellaneous

Free Float
841,000
Market Cap
$3.95 million
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Stanley E. Jacot
    President, Chief Executive Officer & Director
  • Belinda Yao
    Vice President-Operations
  • Thomas J. Schaefer
    Chief Financial Officer
  • Brett Michel
    General Manager
  • Laura Pitlik
    Chief Marketing Officer













RKDA Stock - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings
or view top-rated stocks.

What is Arcadia Biosciences' stock price forecast for 2023?

1 equities research analysts have issued 12-month price targets for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $18.00 to $20.00. On average, they predict the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 313.9% from the stock's current price.
View analysts price targets for RKDA
or view top-rated stocks among Wall Street analysts.

How have RKDA shares performed in 2023?

Arcadia Biosciences' stock was trading at $0.2710 at the start of the year. Since then, RKDA stock has increased by 1,593.7% and is now trading at $4.59.
View the best growth stocks for 2023 here
.

Are investors shorting Arcadia Biosciences?

Arcadia Biosciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 12,400 shares, a decline of 69.8% from the April 30th total of 41,000 shares. Based on an average daily trading volume, of 167,500 shares, the short-interest ratio is presently 0.1 days. Approximately 2.1% of the company's stock are short sold.
View Arcadia Biosciences' Short Interest
.

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RKDA earnings forecast
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its earnings results on Thursday, March, 30th. The basic materials company reported ($6.31) earnings per share (EPS) for the quarter. The basic materials company earned $1 million during the quarter. Arcadia Biosciences had a negative net margin of 245.87% and a negative trailing twelve-month return on equity of 63.53%.

When did Arcadia Biosciences' stock split?

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.62%), Sabby Management LLC (6.16%), State Street Corp (1.42%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer.
View institutional ownership trends
.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $4.59.

How much money does Arcadia Biosciences make?

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.95 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($28.77) on an earnings per share basis.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.

This page (NASDAQ:RKDA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -